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Protein acetylation: more than chromatin modification to 
regulate transcription 
J Henri Bayle and Gerald R Crabtree 
Histone acetyltransferases and deacetylases are involved 
in the regulation of gene transcription. Recently, tumor 
suppressor protein ~53 has been shown to be a target for 
transcriptional coactivators that have histone acetyltrans- 
ferase activity, suggesting acetylation is also involved in 
the regulation of cell proliferation and tumorigenesis. 
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Perhaps the most nebulous role in the control of gene 
expression has been that of chromatin. Although the rate 
of transcription of a gene is clearly controlled by a compli- 
cated interplay of signaling pathways at the promoter, his- 
tones and their modification by acetylation have, until the 
last few years, been the object of much speculation but 
little progress. Recently, a combination of biological and 
chemical approaches have led to the definition of some of 
the enzymes that add or remove acetyl groups on histones. 
The possibility that these enzymes and resulting modifi- 
cations extend their control to processes such as cell prolif- 
eration and protection of the genome by modifying the 
function of ~53 has been raised by recent studies and will 
be the subject of this minireview. 
Figure 1 
The association of histone acetylation with activated 
transcription 
Chromatin structure has been generally correlated with 
transcriptional activity: regions of cytologically dense 
heterochromatin are transcriptionally silent relative to less 
condensed euchromatin. Biochemical analysis using anti- 
bodies that recognize histones acetylated at specific 
amino-terminal residues established that transcriptionally 
active chromatin is enriched for acetylated nucleosomes 
[l], whereas silencing of the mating type cassettes of the 
yeast Saccharomyces cerevisiae correlates with hypoacetyla- 
tion of nucleosomes [Z]. The target sites for acetylation on 
histones H3 and H4 are specific lysine residues on the 
amino-terminal tails that lie outside the nucleosome core. 
The purpose of this acetylation may be to neutralize the 
cationic charge of the amino-terminal tail with the conse- 
quence of destabilizing the interaction of this region with 
DNA and opening chromatin. Acetylated nucleosomes 
have an altered conformation that is more accessible to 
sequence-specific DNA-binding proteins [3]. 
Recently, a series of studies from widely differing experi- 
mental systems have culminated nicely in a new model to 
show how transcription can be regulated through the spe- 
cific recruitment of histone acetylases and deacetylases to 
a promoter (Figure 1). The first evidence implicating the 
recruitment of histone deacetylases to the promoter as a 
mechanism for transcriptional repression came with the 
identification of the biological target of the chemical drug 
trapoxin. Trapoxin is a cell cycle inhibitor known to irre- 
versibly inhibit histone deacetylase activity. Taunton et al. 
[4] reasoned that trapoxin may mimic the structure of an 
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acetylated lysine residue and bind directly to a histone 
deacetylase. Using the activity of trapoxin as part of a 
protein purification strategy, they were able to clone the 
first gene encoding a histone deacetylase termed HDl or 
HDACl [4]. Surprisingly, the primary structure of HDl 
was remarkably homologous with the yeast protein Rpd3. 
Rpd3 had been identified as part of a transcriptional core- 
pressor complex also containing the Sin3 protein [S], but a 
biochemical activity had not yet been characterized for the 
Rpd3 protein. Mammalian homologs of Sin3 can complex 
with HDl. Corepressor complexes containing Sin3-HDl 
appear to lack direct affinity for DNA, but can be 
recruited to target genes by a variety of DNA-binding 
transcriptional repressors, the activity of which can be 
inhibited by trapoxin (reviewed in [6,7]). 
The chemical approach to defining histone deacetylases 
led by Schreiber and colleagues unexpectedly combined 
with the studies of Brownell et al. [8] who succeeded in 
purifying the principal histone acetyltransferase associated 
with transcription from Tetr-ahymena thermophda. The 
cloning of the gene encoding this enzyme revealed that 
the histone acetyltransferase had extensive sequence simi- 
larity to the yeast Gcn5 protein, a component of a coacti- 
vator complex necessary for the function of a number of 
sequence-specific DNA-binding proteins as transcrip- 
tional activators [9]. In mammalian cells, a mammalian 
Gcn5 homolog, termed pCAF, forms a coactivator 
complex with either of the related proteins CBP or ~300 
which also have histone acetyltransferase activity 
(reviewed in [6]). These large proteins can interact with a 
growing number of sequence-specific DNA-binding tran- 
scriptional activator proteins that probably generate the 
gene specificity for their function. 
Acetylation of the ~53 tumor suppressor protein 
Although p300/CBP histone acetyltransferase activity may 
be recruited to promoters to open chromatin structure and 
facilitate transcription, the substrate specificity for the 
enzymatic activity of these proteins is not limited to his- 
tones. The laboratory of Dr. Robert Roeder at Rockefeller 
University [lo] has demonstrated recently that the p53 
tumor suppressor protein is also a target for acetylation by 
~300. ~53 is an important regulator of cell growth that is 
capable of directing the arrest of the cell cycle or the 
induction of apoptosis in response to stress, most notably 
DNA damage [ 11,121. The biochemical activity best corre- 
lated with the antiproliferative effect of ~53 is its ability to 
bind to DNA with sequence specificity and activate tran- 
scription. This function is frequently inactivated during 
carcinogenesis. ~53 is found to be mutated in a large pro- 
portion of human cancers and most mutations map within 
the sequence-specific DNA-binding domain [ll,lZ]. 
Earlier this year, several groups demonstrated that CBP/ 
~300 can bind to and coactivate transcription with p53 
[13-151. The site of interaction is a well-characterized 
amino-terminal transactivation domain that can also inter- 
act with components of the TAF coactivator complex 
[16,17]. Gu and Roeder [lo] found that the site for acetyla- 
tion of p.53 is at the carboxyl terminus of the protein, 
apparently distinct from the amino-terminal site of inter- 
action. The carboxy-temina126 amino acids of ~53 include 
two clusters in which three of four residues are basic; 
lysine at the fourth position of each cluster is preferentially 
acetylated by ~300 in a&o. The authors also provided 
important evidence to show that a transiently expressed 
p.53 can be acetylated in viva in this carboxy-terminal 
region. The proportion of transfected p53 that was acety- 
lated was reported to be low, and it is currently unknown 
what proportion of endogenous ~53 is acetylated in cells. 
Regulation of p53 activity through the carboxyl terminus 
The acetylation of the carboxyl terminus of ~53 has 
important implications for the ability of ~53 to bind to its 
DNA target site. Sequence-specific DNA binding is 
directed by a central domain of ~53; in DNA-binding 
studies, however, ~53 is latent for its interaction with the 
DNA target site through an autoregulatory inhibition 
mediated by the carboxy-terminal 26 amino acids. Binding 
of the carboxyl terminus of ~53 by a specific monoclonal 
antibody, Pab 421, can reverse the inhibition and activate 
~53 for sequence-specific DNA binding [ 181. Alteration of 
the carboxy-terminal 26 amino acids by truncation or alter- 
native mRNA splicing yields a ~53 protein that is constitu- 
tively active for sequence-specific DNA binding [18-211. 
Acetylation of ~53 by ~300 thereby is an attractive means 
of regulating ~53 function. In fact, acetylation at the car- 
boxy1 terminus was shown to dramatically activate the 
latent DNA-binding activity of ~53 [lo]. Inhibition of 
sequence-specific DNA binding is likely to be directed by 
electrostatic interactions through basic residues present in 
the carboxyl terminus; acetylation serves to neutralize the 
charge of the lysine sidechain and activate ~53. 
The mechanism by which the carboxyl terminus of ~53 
inhibits the core sequence-specific DNA-binding domain 
is still debated (Figure 2). One model proposes that 
residues at the carboxyl terminus interact with the core 
DNA-binding domain, placing ~53 in a conformation that 
is refractory to DNA binding [Z&23]. Such an interaction is 
proposed to be directed by the basic residues at the car- 
boxy1 terminus and can be blocked by modification of the 
carboxyl terminus, such as acetylation, leading to an 
allosteric transition within ~53 to a sequence-specific 
DNA-binding conformation. Support for this model has 
come from the observation that the carboxy-terminal 
domain or synthetic peptides derived from this region are 
able to activate latent ~53 in tram for sequence-specific 
DNA binding in V&O [Z&23]. The peptides are proposed 
to block the intramolecular interaction of the carboxyl ter- 
minus with the core DNA-binding domain by competition, 
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Figure 2 
Two models to explain how acetylation of the 
carboxyl terminus of the p53 protein can 
activate latent sequence-specific DNA 
binding. (a) The carboxyl terminus (depicted 
as a tail) interacts with the core sequence- 
specific DNA-binding domain of ~53. 
Acetylation of lysine residues by p300/CBP 
disrupts this binding and changes the 
conformation of ~53 to allow bindina to its 
Acetylation 
target sequence’(depicted in blue). - 
(b) binding to excess nonspecific competitor 
DNA by the basic carboxyl terminus of p53 
sequesters the sequence-specific DNA- 
binding domain from interacting with its target 
sequence. Acetylation of the carboxyl 
terminus inhibits its nonspecific DNA binding 
and allows sequence-specific DNA binding to 
occur. Details are presented in the text. 
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while lacking inhibitory activity themselves. Very high 
concentrations of peptide or the carboxy-terminal domain 
are required to direct the activation of p53 in tram which 
may indicate that the interaction of these peptides with the 
core domain is very weak relative to the same sequences 
on the intact protein. 
Another plausible mechanism for the inhibition of 
sequence-specific DNA binding by the carboxy-terminal 
domain of ~53 concerns a biochemical activity intrinsic to 
the domain: binding to nucleic acids without sequence 
specificity. The carboxy-terminal domain of ~53 is suffi- 
cient to direct binding to DNA and can actually catalyze 
the annealing of single strands of complementary DNA or 
RNA sequences [19,24,25]. This activity can be disrupted 
by antibody binding or by alteration of the structure of the 
carboxyl terminus [21,24]. Because the same modifications 
to the carboxyl terminus can also activate sequence-spe- 
cific DNA binding, it was proposed that latency of 
sequence-specific DNA binding is mediated by nonspe- 
cific DNA binding by the carboxyl terminus, precluding 
the binding of p53 to its specific DNA target. In fact, it 
has been observed that increasing amounts of nonspecific 
double-stranded DNA can strongly inhibit sequence-spe- 
cific DNA binding by ~53, but not when the carboxyl ter- 
minus is altered by deletion or by antibody binding [21]. 
Interestingly, however, short (< 25 nucleotide) oligonu- 
cleotides were observed to activate latent p53 [22]. 
Sequence-nonspecific DNA binding by the carboxyl ter- 
minus of p53 may be mediated through the interaction of 
the basic residues in the carboxy-terminal region with the 
phosphodiester backbone. Acetylation of lysine in this 
region is likely to disrupt the interaction with nonspecific 
DNA and thereby free p53 to bind to its target site and 
activate the transcription of downstream targets, such as 
p21 and bax, that inhibit cell proliferation. Such a mecha- 
nism may explain why very high concentrations of 
carboxy-terminal peptide are required to activate p53 in 
tram, as these concentrations approach that of the nonspe- 
cific competitor DNA typically added to in vitro DNA- 
binding reactions and may saturate the DNA preventing 
the intact p53 from interacting with this inhibitor. 
Prospects and predlctions 
Whatever the mechanism of the latency of sequence-spe- 
cific DNA binding might be, it is clear that carboxy-termi- 
nal acetylation may be an important activation mechanism 
for p53 function. The relevance of acetylation at the car- 
boxy1 terminus of p53 to p53 function in &JO promises to 
be an active avenue of investigation. It will be essential to 
determine whether acetylation of p53 is altered during the 
cellular response to DNA damage. p53 levels and tran- 
scriptional activity are dramatically increased in response 
to DNA damage caused by a stabilization of the normally 
labile p53 protein. The proportion of acetylated p53 that is 
acetylated in vjvo is reported to be low [lo]. Is the propor- 
tion of transfected p53 increased in response to DNA 
damage? Does acetylation of p.53 influence the half-life of 
the protein as well as the DNA-binding activity? 
The reversibility of p53 acetylation will also be an inter- 
esting issue to address. The tonic level of p53 activity may 
be controlled then by the balance of acetylase activity 
through p300/CBP and by as yet uncharacterized deacety- 
lases. In this regard, it is curious that trapoxin, an irre- 
versible inhibitor of HDACl, induces cell cycle arrest or 
apoptosis in some cell types, each responses that can also 
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be directed by induction of wild-type ~53. Perhaps the 
effects of trapoxin are caused by inhibiting the deacetyla- 
tion of ~53, shifting the balance of ~53 cowards an acety- 
lated and activated form that can arrest cell proliferation. 
It is probably worth determining whether trapoxin is able 
to induce growth arrest or apoptosis in cells lacking ~53. 
The demonstration of ~53 acetylation by transcriptional 
cofactors previously known as histone specific acetyltrans- 
ferases suggests that protein acetylation and deacetylation 
may possibly be important regulatory modifications in 
other systems. Although the CREB transcription factor, for 
which CBP is a coactivator, is not apparently a substrate for 
acetylation [lo], a recent paper has shown that two compo- 
nents of the general transcription machinery, TFIIE and 
TFIIF, can be acetylated by several histone acetyltrans- 
ferases [26]. These coactivators may therefore influence 
transcriptional activation and elongation by mechanisms 
distinct from their effect on chromatin structure. The 
design of inhibitors of acetylases will probably be important 
for determining the specific roles of these proteins during a 
process as complex as transcription, and it may help to 
define roles for these proteins in other cellular processes. 
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